Clinical Trial Detail

NCT ID NCT02781883
Title Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With LDAC in Patients With Previously Untreated AML
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bio-Path Holdings, Inc.
Indications

acute myeloid leukemia

Therapies

BP1001 + Cytarabine

Age Groups: senior adult

No variant requirements are available.